Preliminary results of the clinical study, being conducted at the University of Rochester School of Medicine and Dentistry, showed that six months of treatment with doses of Insmed's IPLEX in myotonic dystrophy up to 1mg/kg/day in six patients met the primary study endpoints of being safe and well-tolerated. In addition, IPLEX treatment was associated with improvements in muscle mass, cholesterol and triglycerides.
During the six months of treatment, five out of six patients experienced an improvement in lean muscle mass. Patients also reported improvement in gastrointestinal function, endurance and cognitive function during treatment with IPLEX.
The positive news pushed Insmed's share price 6.1% higher to $1.0 in morning tading on the Nasdaq on May 3.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze